BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33546481)

  • 1. PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates.
    Li Q; Li W; Xu K; Xing Y; Shi H; Jing Z; Li S; Hong Z
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody-Drug Conjugates.
    Xu K; Han J; Yang L; Cao L; Li S; Hong Z
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates.
    Chen B; Gianolio DA; Stefano JE; Manning CM; Gregory RC; Busch MM; Brondyk WH; Miller RJ; Dhal PK
    ChemMedChem; 2018 Apr; 13(8):790-794. PubMed ID: 29517131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
    Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X
    Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
    Dela Cruz Chuh J; Go M; Chen Y; Guo J; Rafidi H; Mandikian D; Sun Y; Lin Z; Schneider K; Zhang P; Vij R; Sharpnack D; Chan P; de la Cruz C; Sadowsky J; Seshasayee D; Koerber JT; Pillow TH; Phillips GD; Rowntree RK; Boswell CA; Kozak KR; Polson AG; Polakis P; Yu SF; Dragovich PS; Agard NJ
    MAbs; 2021; 13(1):1862452. PubMed ID: 33382956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
    Tedeschini T; Campara B; Grigoletto A; Bellini M; Salvalaio M; Matsuno Y; Suzuki A; Yoshioka H; Pasut G
    J Control Release; 2021 Sep; 337():431-447. PubMed ID: 34329685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unlocking the potential of antibody-drug conjugates for cancer therapy.
    Drago JZ; Modi S; Chandarlapaty S
    Nat Rev Clin Oncol; 2021 Jun; 18(6):327-344. PubMed ID: 33558752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
    Kumar A; Mao S; Dimasi N; Gao C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
    Singh AP; Sharma S; Shah DK
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
    Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
    Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.